Inactive Instrument

Company Centrexion Therapeutics Corporation

Equities

CNTX

US15643W1009

Biotechnology & Medical Research

Business Summary

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.

Number of employees: 24

Managers

Managers TitleAgeSince
Founder 76 13-01-31
Founder 68 13-01-31
Chief Tech/Sci/R&D Officer - 15-03-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 72 18-06-25
Founder 76 13-01-31
Founder 68 13-01-31
Director/Board Member 73 -
Director/Board Member 83 13-01-31
Director/Board Member 60 18-08-14
Founder 76 13-01-31
Director/Board Member 75 17-12-31
Director/Board Member 65 17-06-25
Director/Board Member 53 17-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,669,866 0 0 -

Company contact information

Centrexion Therapeutics Corp.

200 State Street 6th floor

02109, Boston

+617-837-6911

http://www.centrexion.com
address Centrexion Therapeutics Corporation(CNTX)